▲ This photo, provided by South Korean biopharmaceutical firm Samsung Bioepis Co. on Aug. 23, 2021, shows the company's headquarters. (PHOTO NOT FOR SALE) (Yonhap)

Samsung Bioepis-global sales

Global sales of Samsung Bioepis' 5 biosimilars surpass 1 tln won in 2021

By Kim Han-joo

SEOUL, Nov. 12 (Yonhap) -- Samsung Bioepis Co., a South Korean biopharmaceutical company, said Friday that global sales of its five biosimilar products, excluding the South Korean market, surpassed 1 trillion won (US$847 million) this year.

The combined sales of the five biosimilars -- Infliximab, Etanercept, Adalimumab, Trastuzumab and Bevacizumab -- came to $916.2 billion in the January-September period, up 11 percent from the same period a year earlier, the company said.

The company cited earnings reports of its global partners -- Oganon International and Biogen Inc.

Noticeably, global sales of Trastuzumab jumped 28 percent on-year to $110 million this year. The breast cancer biosimilar Trastuzumab, also known as Ontruzant, references Switzerland-based Roche Holding's Herceptin.

Samsung Bioepis is a joint venture between Biogen Inc. and Samsung Biologics Co., one of the world's major contract drug manufacturers.

(END)

[ⓒ K-VIBE. 무단전재-재배포 금지]